Modern, non-steroidal aromatase inhibitors (AIs) are widely used, effective treatments for ER+ve breast cancer [21], [22] and are also excellent pharmacological probes for oestrogen-dependent processes in vivo because of their specificity and highly effective suppression of oestrogen synthesis. The gene discussed is ESR1; the disease is breast carcinoma.